Collectively, we demonstrate that PD-1/TDE-PD-L2 axis systematically suppresses T cell functions, representing a potentially therapeutic strategy for ccRCC treatment. This evidence concerns the gene PDCD1 and nonpapillary renal cell carcinoma.